Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2017 (pdf):
download in single page format - double page (broad) format

Publication overview

Current news and events

How do cells keep their assembly lines in synchrony?

First author Carmen Herrera and senior author Jorrit Enserink

A new study by a team from the Institute for Cancer Research and the Norwegian Centre of Excellence CanCell provides novel in sight in the mechanisms by which cells maintain synchrony in their biosynthetic processes. Using the model organism budding yeast, Herrera et al discovered a new regulatory mechanism by which cells may keep protein synthesis in synchrony with cell division. In brief, they discovered that a protein called cyclin dependent kinase (Cdk1), which is the master regulator of the cell cycle, localizes to tRNA genes during a brief period in the cell cycle. The results have recently (22 September) been published in the prestigious journal Nucleic Acids Research.

Research team from Oslo and Eindhoven discovers wound healing without a woundA mere drop of blood makes skin cells line up

Emma Lång and Stig Ove Bøe

What happens to skin cells when they are confronted with blood? A team of researchers from Oslo University Hospital, led by Emma Lång and Stig Ove Bøe, performed experiments on blood-deprived cells that were subsequently exposed to blood serum. Remarkably, all the cells started to move and grow in the same direction as soon as the blood serum was added. Assistant Professor Liesbeth Janssen and student Marijke Valk from Eindhoven University of Technology (TU/e) developed a matching simulation model, revealing new insights into the mechanisms of wound healing. The results have recently been published in the journal Nature Communications.

UiO Research Award ceremony Sept 3rdHarald Stenmark interviewed for Uniforum

Harald Stenmark (photo: Ola Sæther, Uniforum)

On Monday September 3rd professor Harald Stenmark from the Department of Molecular Biology at the Institute for Cancer Research will receive the prestigious University of Oslo Research Award for 2018 during the annual anniversary party in the University Aula. Stenmark has been interviewed by Martin Toft for the UiO newpaper Uniforum, where his very successful ongoing career is chronicled. The article is entitled "Hunting for the Achilles heels of Cancer".
Together with other award winners Stenmark gave a short lecture about his research in the library in the Vilhelm Bjerknes building the same Monday.

Nature Communications publication selected for Editor's Highlight webpage:A study of the epigenetics of breast cancer provides clues to mechanisms behind subtypes of the disease

Photo: Daniel Nebdal.
(image capiton under "More")

Thomas Fleischer and Xavier Tekpli from the Cancer Genome Variation group, led by Vessela Kristensen at the Department of Cancer Genetics, IKF, together with their collaborators from the NCMM, Toni Hurtado and Anthony Mathelier, and Professor Arnoldo Frigessi from UiO identified methylated regions (CpGs) that show remarkably and reproducibly conserved patterns of association to gene expression in the DNA from breast tumors in three independent breast cancer cohorts. 
The article - entitled “DNA methylation at enhancers identifies distinct breast cancer lineages” has been selected for the Editors’ Highlights webpage of recent research on Genomes and Epigenomes, put together by the editors at Nature Communications.

Molecular Cancer Therapeutics article from Namløs, Boye and Meza-Zepeda:ctDNA reveals tumour heterogeneity and burden in gastrointestinal stromal tumours

Shared first authors Heidi Namløs and Kjetil Boye and senior author Leonardo Meza-Zepeda

Imatinib treatment has been very successful in gastrointestinal stromal tumour (GIST), where an initial treatment response is seen for the majority of the patients. However, over time the tumours evolve and get resistant to the treatment. GISTs are characterised by mutations in tyrosine kinase receptors KIT and PDGFRA, which are important for treatment decisions. There is a need to establish patient-friendly means/methods to obtain tumour material for mutational testing, which can ultimately improve the treatment of GIST patients.

Wednesday 22nd of AugustCelebration of Harald Stenmark’s ERC Advanced Grant

Harald Stenmark (left) and Bjørn Erikstein

The second ERC Advanced Grant to Professor Harald Stenmark, director of the Centre of Excellence “Centre for Cancer Cell Reprogramming” at the Institute of Clinical Medicine, UiO, and head of the "Cellular membrane dynamics" group and the Department of  Molecular Cell Biology, Institute for Cancer Research, OUH was celebrated on 22nd of August.

Through this prestigious grant from the European Research Council, Stenmark's research project "Coincidence detection of proteins and lipids in regulation of cellular membrane dynamics (CODE)" is supported with 2.5 million Euros over a 5-year period.

Units and subpages

View all subunitsHide all subunits